Skip to main content

Harvard Licenses Nasal Swab Collection Tech to Rhinostics

NEW YORK — Harvard University said on Tuesday that it has licensed a nasal swab collection technology developed at its Wyss Institute for Biologically Inspired Engineering to startup Rhinostics.

Unlike traditional nasal swabs, which are manufactured in two parts that require assembly, the Wyss swabs are fully injection-molded from a single material and can be manufactured in a less expensive, one-step process, according to Harvard. In clinical testing, the swab design has been shown to effectively collect SARS-CoV-2 RNA from nasopharyngeal samples and is compatible with automated instrumentation.

Cambridge, Massachusetts-based Rhinostics plans to use the technology to develop and commercialize automated and multiplexed products for processing nasal samples for SARS-CoV-2 and other respiratory infection testing. Harvard said that the license gives Rhinostics exclusive rights to the nasal swab technology for non-SARS-CoV-2 related applications.

Financial and other terms of the deal were not disclosed.

Rhinostics, which was cofounded by Wyss researchers Richard Novak and Michael Springer, named Cheri Walker as its president and CEO in late 2020.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.